Novartis backed Viamet Pharmaceuticals refiles for a $100 million IPO

Viamet Pharmaceuticals Holdings, a biotech developing small molecule metalloenzyme inhibitors to treat fungal diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

The Durham, NC-based company was founded in 2004. It plans to list on the Nasdaq under the symbol VMET. Morgan Stanley, Goldman Sachs, Guggenheim Securities and Needham & Co. are the joint bookrunners on the deal. No pricing terms were disclosed.